US › Healthcare

Sinovac Biotech Ltd (SVA)

US · Healthcare · Biotechnology

$6.470.00%
Last close · 2026-08-04

Latest quarter · ended 2023-12-31

Revenue
$307.9M
Revenue YoY
-74.6%
Net profit
$-116.8M
Profit YoY
-124.1%
EPS
$-0.11
EPS estimate
$-0.03
Net margin
-38.0%

EPS came in at -0.11 against a street estimate of -0.03 — a miss of 266.7%.

Key statistics

Market cap
$642.4M
P/E
6.7
Forward P/E
357.1
P/B
1.82
Book value
$7.52
EPS (TTM)
$0.97
52-week high
$6.47
52-week low
$6.47
50-day MA
$6.47
200-day MA
$6.47
Beta
0.06

Analyst view

with an average price target of $3.52.

Shareholding

Insiders
51.42%
Institutions
32.02%

Largest institutional holders

FundStake
Vivo Capital, LLC8.21%
Orbimed Advisors, LLC3.78%
Renaissance Technologies Corp1.83%
Neumann Advisory Hong Kong Ltd0.44%
Skandinaviska Enskilda Banken AB0.11%
California Public Employees Retrmnt Sys0.10%
Spark Investment Management LLC0.04%
Geode Capital Management, LLC0.04%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Sinovac Biotech Ltd — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.